[关键词]
[摘要]
目的:通过系统评价和Meta分析,以确定眼部水溶液样本中IL-8水平与糖尿病视网膜病变(DR)之间的关系。
方法:检索PubMed、Embase和Web of Science数据库,检索时间为2010-01/2021-06。采用随机效应模型合并结果,通过敏感性分析确定运算结果是否稳定可靠,并且采用亚组分析寻找异质性可能的来源。
结果:共纳入25篇病例对照研究。DR患者的IL-8水平明显高于非DR患者(SMD:1.57,95%CI:1.19~1.95,P<0.01)。敏感性分析提示随机效应的运算结果是稳定可靠的。基于检测方法、地区、样本来源、DR类型的亚组分析显示,这些因素的选择在很大程度上会影响IL-8水平与DR患者的关系。其中,来自Bead-based法(I2=18%,P=0.27)、欧洲(I2=38%,P=0.17)和非增殖性糖尿病视网膜病变(NPDR)(I2=0%,P=0.49)样本的一致性比较好。而ELISA、美洲、亚洲、玻璃体液、增殖性糖尿病视网膜病变(PDR)等因素都可能会加大效应量。
结论:眼部水溶液中IL-8水平升高与DR的发生风险有关,IL-8可作为DR的潜在预测因子或治疗靶点。
[Key word]
[Abstract]
AIM: To determine the relationship between interleukin-8(IL-8)levels in aqueous ocular samples and diabetic retinopathy(DR)through systematic evaluation and Meta-analysis.
METHODS: The PubMed, Embase and Web of Science database were searched from January 2010 to June 2021. A random effects model was used to combine the results, and the sensitivity analysis was performed to determine the stability and reliability of the arithmetic results, and subgroup analysis was used to identify possible sources of heterogeneity.
RESULTS: A total of 25 case-control studies were included. IL-8 levels in patients with DR were significantly higher than those in patients without DR(SMD: 1.57, 95%CI: 1.19-1.95, P<0.01). Sensitivity analysis shows that the calculation results of random effects are stable and reliable. Subgroup analysis based on test method, region, sample source, and type of DR showed that the choice of these factors greatly influenced the relationship between IL-8 levels and patients with DR. Among them, the samples from Bead-based multivariate analysis(I 2=18%, P=0.27), Europe(I 2=38%, P=0.17)and nonproliferative diabetic retinopathy(NPDR)(I 2=0%, P=0.49)showed good consistency. ELISA, American, Asian, vitreous fluid, proliferative diabetic retinopathy(PDR)and other factors may increase the effect size.
CONCLUSION: Elevated IL-8 levels in aqueous eye solution are associated with the risk of DR, and IL-8 may serve as a potential predictor or therapeutic target for DR.
[中图分类号]
[基金项目]
中医药循证能力建设项目(No.2019XZZX-YK009); 山东省中医药科技发展计划项目(No.2019-0086)